An interventional study of REACH West in Skin Cancer Prevention and Sun Safety, sponsored by University of Utah. Enrolling by invitation at 1 site in United States. Open to participants aged 12 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Utah · Not applicable, Interventional, and Prevention
Among 379 studies in Skin Neoplasms with a site in United States — 62 open to participants now, 96 under way, 7 of them phase 3. Skin Neoplasms · United States.
Among the 379 studies in Skin Neoplasms with a site in United States, this one is the 35th largest by planned enrollment of the 288 interventional ones that give a count, is one of 16 that started in 2026, is one of 96 with no phase, reaches primary completion later than 45 of the 94 other live ones, and was the 378th registered.
604 studies on the registry are indexed under Skin Neoplasms; 126 are open to participants now.
Browse Skin Neoplasms studies →62 of the 379 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 13+ · Healthy volunteers
University of Utah · Sites in United States
Ages 18–29 · Healthy volunteers
Marissa Lobl · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Skin Neoplasms studies recruiting now, 84 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.
This study: 12 Years to 21 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
379 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 114 · Phase 3 26 · Phase 4 11
First in 1977; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 55 across 408 interventional studies indexed under Skin Neoplasms.
Median enrollment 44 across the 288 interventional studies, 149 across the 80 observational. Of the 258 that completed or were terminated, 92 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 379 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 994 studies on the registry; 175 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 8 studies filed under Skin Neoplasms — fewer than ten, so there is no comparison to draw.
33 of the studies in Skin Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT05634252Phase 3University of UtahUndergraduate Skin Cancer Prevention Trial | 2027-09-04 |
| NCT07201376Dartmouth-Hitchcock Medical CenterAssessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically | 2026-11 |
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
Among the 379 studies in Skin Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project will deliver a sun safety education presentation to high schools in the mountain west (e.g., Montana, Wyoming, and Idaho) who are at high melanoma risk. Feasibility, acceptability, and preliminary effects of the intervention on sun safety behaviors and other skin cancer-related outcomes will be assessed.
Recruitment and Enrollment
Staff, teachers, and relevant school groups (e.g. PTAs, district nurses, etc) at either the district or school-level will be emailed or called to recruit teachers to enroll in the study. If schools/districts require research applications to proceed, those will be submitted. If a teacher is interested, they will participate in an enrollment call to learn more about the study and determine their eligibility. If eligible, at the end or after the call, the teacher will be sent a consent form to enroll in the study.
Parents and students will be recruited by being connected to the participating teacher (being a student of the teacher or by being a parent of a student). Parents will be recruited by being sent a parental permission form via digital or paper methods. For digital recruitment, the teacher will send the REDCap form via any platform the teacher uses to communicate with parents (e.g. Canvas, email, texting apps).
Students will be recruited by being emailed and texted their assent/consent form and baseline survey to their collected contact information the research team received from their parent and teacher. Teachers will also devote class time for students to take their baseline survey to promote recruitment. In some cases, study staff may visit the classes to promote the study as well.
Intervention
During the process of the teacher enrolling and gathering parental permission, study staff will schedule the intervention date(s). Teachers will be provided an all-inclusive Canvas course that they will download into their Canvas account for their class. This course will be a 70-minute educational presentation about skin cancer with associated activities for the students.
Post intervention
After the intervention, students will take an immediate post-intervention survey and one-month follow up survey. These will be delivered via digital (e.g. text, email, etc.) and/or in-person methods. Teachers will take an immediate post-intervention survey, along with being invited to participate in a qualitative interview. After the one-month follow-up survey, a subset of parents and students will be invited to participate in a separate or combined qualitative interview.
Inclusion Criteria for teachers:
Inclusion Criteria for students:
Inclusion Criteria for parents:
Exclusion Criteria for teachers:
Exclusion Criteria for students:
Exclusion Criteria for parents:
Students will receive a digital educational modules on sun safety and skin cancer education.
Behavioral: REACH West
REACH West is a digital educational intervention on sun safety and skin cancer prevention for high school students.
Percentage of teachers who completed the intervention without major technical issues
To measure the intervention feasibility, we will measure the percentage of teachers that completed delivery of the intervention without major technical issues. This is measured by a post-intervention interview that asks, 'Did you encounter any challenges in using the REACH West curriculum in utilizing/accessing the online Canvas modules?' A lower percent of teachers who report encountering issues is a better outcome.
Time frame: One Month Post Intervention
Mean of Intervention Acceptability via AIM
We will measure teachers' self-reported acceptability with the intervention via AIM (Acceptability of Intervention Measure). This is measured through four 5-point Likert scale statements (completely disagree to completely agree): * REACH West meets my approval. * REACH West is appealing to me. * I like REACH West. * I welcome REACH West. A higher score indicates a better outcome.
Time frame: Immediately Post Intervention
Mean of Student Tanning Occurrence
We will measure students' self-reported tanning occurrence of the past month. This will include responses to unintentional and intentional tanning questions. Questions include: In the past month, how many times did you.. * Use an indoor tanning device such as a sunlamp, sunbed or tanning booth? (Do not count getting a spray-on tan) * Sunbathe or tan outdoors? * End up with a tan, even if you didn't try to get one? A lower number indicates a better outcome.
Time frame: Baseline, 1-Month Post-Intervention
Mean of Student Sun Protection Behaviors
We will measure students' self-reported sun safety behaviors of the past month. This is measured by eight 5-point likert scale items (never to always). Statements include: In the past month, when you were outdoors in the sun for 15 minutes or more, how often did you... * use sunscreen? * re-apply sunscreen after being outside for 2 hours, in the water, or sweating? * wear a shirt with sleeves that cover your shoulders? * wear long pants or a long skirt? * wear a hat? * stay in shade or under an umbrella? * avoid being in the sun between 10:00am-4:00pm? * wear sunglasses? A higher score indicates a better outcome.
Time frame: Baseline, 1-month post-intervention
PDFs hosted by the registry, ClinicalTrials.gov.
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
Of 94 non-industry interventional studies with no phase under Skin Neoplasms, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 8 months is below that.
Counting every sponsor, half of 116 studies reached it within 27 months; a quarter within 10 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.